CA2263998A1 - Compositions and methods for administering integrin receptor antagonists - Google Patents

Compositions and methods for administering integrin receptor antagonists Download PDF

Info

Publication number
CA2263998A1
CA2263998A1 CA002263998A CA2263998A CA2263998A1 CA 2263998 A1 CA2263998 A1 CA 2263998A1 CA 002263998 A CA002263998 A CA 002263998A CA 2263998 A CA2263998 A CA 2263998A CA 2263998 A1 CA2263998 A1 CA 2263998A1
Authority
CA
Canada
Prior art keywords
composition
inhibiting
patient
receptor antagonist
integrin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002263998A
Other languages
English (en)
French (fr)
Inventor
Michael F. Sugrue
Robert J. Gould
George D. Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9619583.9A external-priority patent/GB9619583D0/en
Application filed by Individual filed Critical Individual
Publication of CA2263998A1 publication Critical patent/CA2263998A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002263998A 1996-08-29 1997-08-25 Compositions and methods for administering integrin receptor antagonists Abandoned CA2263998A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2580896P 1996-08-29 1996-08-29
US60/025,808 1996-08-29
GBGB9619583.9A GB9619583D0 (en) 1996-09-19 1996-09-19 Compositions and methods for administering integrin receptor antagonists
GB9619583.9 1996-09-19
PCT/US1997/014908 WO1998008518A1 (en) 1996-08-29 1997-08-25 Compositions and methods for administering integrin receptor antagonists

Publications (1)

Publication Number Publication Date
CA2263998A1 true CA2263998A1 (en) 1998-03-05

Family

ID=26310068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002263998A Abandoned CA2263998A1 (en) 1996-08-29 1997-08-25 Compositions and methods for administering integrin receptor antagonists

Country Status (5)

Country Link
EP (1) EP0928194A4 (ja)
JP (1) JP2001501597A (ja)
AU (1) AU729488B2 (ja)
CA (1) CA2263998A1 (ja)
WO (1) WO1998008518A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067972A1 (en) * 2001-02-28 2002-09-06 Duke University Method of inducing vitreous detachment
JP2007005582A (ja) 2005-06-24 2007-01-11 Asm Japan Kk 基板搬送装置及びそれを搭載した半導体基板製造装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
EP0557406A4 (en) * 1990-11-01 1993-10-06 Smith-Kline Beecham Corporation -g(g)-turn peptidomimetics as fibrinogen antagonists
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten

Also Published As

Publication number Publication date
AU4086297A (en) 1998-03-19
EP0928194A1 (en) 1999-07-14
EP0928194A4 (en) 2001-01-17
AU729488B2 (en) 2001-02-01
WO1998008518A1 (en) 1998-03-05
JP2001501597A (ja) 2001-02-06

Similar Documents

Publication Publication Date Title
US11911379B2 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US20030181462A1 (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
EP0760658B1 (en) Compounds for inhibiting osteoclast-mediated bone resorption
EP0901373B1 (en) Alpha v Beta 3 ANTAGONISTS
US20040152745A1 (en) Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
JP2001504456A (ja) インテグリン拮抗薬
US6403571B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
JP2011252012A (ja) シクロペプチドおよび化学治療剤または血管新生阻害剤を含有する医薬製剤
US6251852B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
EP1420790B1 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
WO1997035579A1 (en) A method for inhibiting clot formation
US5925655A (en) αv β3 antagonists
AU740941B2 (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US5900414A (en) Methods for administering integrin receptor antagonists
AU729488B2 (en) Compositions and methods for administering integrin receptor antagonists
GB2327672A (en) 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
CA2234364C (en) Compositions for inhibiting platelet aggregation
WO2020203822A1 (ja) 血管新生を伴う網膜疾患の治療又は予防のための併用医薬
JPH0426631A (ja) 血管新生抑制剤
US20030139342A1 (en) Method of inducing vitreous detachment
JP2800412B2 (ja) 免疫抑制作用増強剤
WO2002020566A2 (de) NEUE MMP-2-DERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿3?
AU2002333393A1 (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
CA2268916A1 (en) Integrin antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead